Central to the ACTM-838 approach is its capacity to systemically administer a live attenuated bacterial vector optimized for tumor localization. Upon intravenous delivery, this modified Salmonella Typhimurium strain preferentially accumulates within solid tumors, exploiting its innate ability to target phagocytic cells residing in the TME. This selective tropism facilitates concentrated delivery of therapeutic proteins while minimizing exposure to healthy tissues, thereby substantially mitigating systemic toxicity—a significant concern in earlier bacterial therapies.

The payload delivered by ACTM-838 comprises a sophisticated fusion of immune agonists: the interleukin-15/interleukin-15 receptor alpha complex (IL-15/IL-15Rα) alongside a modified Stimulator of Interferon Genes (STING) agonist. IL-15/IL-15Rα plays a pivotal role in stimulating the proliferation and activation of cytotoxic lymphocytes, fostering robust adaptive immune responses. Meanwhile, the STING pathway acts as a critical sensor within innate immunity, activating type I interferon responses essential for initiating potent anti-tumor immunity. The architectural design of ACTM-838 ensures co-delivery of these complementary factors to reprogram the immunosuppressive TME towards an immunogenic milieu conducive to sustained tumor eradication.

Preclinical investigations detailed in the study demonstrate ACTM-838’s remarkable ability to trigger tumor regression across multiple murine models, including notoriously treatment-resistant variants. This bacterially-mediated therapy not only facilitated significant tumor shrinkage but also conferred durable protection, as evidenced by rechallenge experiments where cured mice resisted tumor recurrence. Such findings suggest the establishment of durable immune memory, a holy grail of cancer immunotherapy aimed at preventing relapse.

Moreover, ACTM-838’s synergy with immune checkpoint blockade therapies such as anti-PD1 monoclonal antibodies underscores its potential clinical utility. Combination treatment regimens exhibited enhanced efficacy beyond monotherapies, reshaping tumor immune landscapes to favor effector T-cell infiltration and reducing immunosuppressive regulatory T-cells and exhausted phenotypes. This dual modality exemplifies the promise of integrating bacterial vectors with existing immunotherapeutic agents to surmount current treatment ceiling effects.

On a mechanistic level, single-cell RNA sequencing analyses revealed novel myeloid subsets that emerge within the TME following ACTM-838 administration. These subsets include proliferative macrophages and metabolically reprogrammed neutrophil populations characterized by distinct transcriptional signatures. Such cellular dynamics underscore the complex innate immune orchestration initiated by this therapy, which collectively drives adaptive response amplification and tumor immune sensitization.

Importantly, the study addresses safety concerns by demonstrating that ACTM-838 markedly reduces inflammatory toxicity compared to its parental bacterial strain. Genetic attenuation strategies curtailed pathogenicity without compromising delivery efficacy, thereby achieving a favorable therapeutic index critical for translational potential. This balance between safety and potency positions ACTM-838 as a viable candidate for progression into clinical trials.

The implications of this research stretch beyond the immediate therapeutic benefits, offering a paradigm shift in delivering multiplexed gene-based immune modulators to the tumor site. By harnessing live bacterial platforms engineered for specific payload delivery, researchers open avenues for versatile, adaptable cancer treatments tailored to diverse tumor types and resistant phenotypes, a significant leap from conventional systemic immunotherapies.

ACTM-838 is currently undergoing Phase I clinical trials, marking a significant milestone in translational oncology research. These trials will probe tolerability, biodistribution, and early efficacy signals in human subjects, setting the stage for potential regulatory approvals and widespread clinical application. Success in these early-phase trials could catalyze a wave of bacterial-based immunotherapies entering the oncological arsenal.

The novelty of ACTM-838 underscores the broader trend of synthetic biology and genetic engineering converging to transform therapeutics. This live bacterial vector harnesses cutting-edge genetic manipulation to introduce complex immunomodulatory payloads that are otherwise challenging to deliver systemically due to bioavailability and toxicity constraints. Such innovations align with the global pursuit of precision oncology.

As the field moves forward, integration of live bacterial therapies with personalized medicine frameworks offers enticing prospects. Tailoring payload combinations and dosing regimens based on individual tumor immunoprofiles could maximize therapeutic responsiveness while minimizing adverse events—objectives at the forefront of next-generation cancer treatment paradigms.

In summary, ACTM-838 exemplifies a sophisticated and promising approach that merges microbial engineering with immuno-oncology to tackle the formidable challenge posed by solid tumors’ immune evasion. Its capacity to safely deliver IL-15/IL-15Rα and STING agonists within the tumor microenvironment, stimulate both innate and adaptive immunity, and generate durable anti-tumor effects positions it as a beacon of hope for patients unresponsive to existing therapies. This pioneering research paves the way for an exciting era where live bacterial therapies redefine the boundaries of cancer treatment.

Subject of Research: Not applicable

Article Title: ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response

News Publication Date: 6-Oct-2025

Web References:

• Article DOI: 10.18632/oncotarget.28769
• Actym Therapeutics: https://www.actymthera.com/
• Oncotarget: https://www.oncotarget.com/archive/v16/

Image Credits: Copyright: © 2025 Cron et al. This is an open access article under CC BY 4.0 license.

Keywords: cancer, oncology, tumor microenvironment, bacterial vector, myeloid cells, STING, IL-15

At the core of this system is a strain of Salmonella typhimurium, a bacterium renowned for its innate ability to home in on hypoxic, nutrient-rich tumor microenvironments. Leveraging this natural homing instinct, the research team has engineered the bacteria to transport a picornavirus stealthily into solid tumors. Once inside the tumor’s interior, the bacteria invade cancerous cells and undergo programmed lysis, releasing the viral RNA payload precisely where it is most effective. This clever Trojan horse strategy not only ensures precise localization of the virus but also maximizes its oncolytic potential by circumventing systemic immune defenses that commonly neutralize free viruses in circulation.

One of the critical impediments to effective oncolytic viral therapy is the host immune system’s pre-existing immunity to common viruses, which often results in rapid neutralization of therapeutic viruses before they reach tumor sites. The CAPPSID platform ingeniously addresses this limitation by using bacteria as protective carriers. These bacteria cloak the virus from neutralizing antibodies encountered in the bloodstream, allowing the viral payload to reach the tumor intact. This mechanism promises to extend the clinical applicability of viral therapies to patients who have pre-existing immunity, a patient population that has historically presented significant challenges for oncolytic virus therapeutics.

The engineered bacteria-virus consortium creates a sophisticated interdependent system. The virus’s replication and maturation processes are engineered to rely on a specific bacterial enzyme—a protease—that is exclusively present within the tumor environment where the engineered bacteria reside. This molecular dependency restricts viral propagation to the vicinity of the tumor, effectively locking viral replication to the tumor microenvironment and preventing deleterious spread to healthy tissues. This safety mechanism is a substantial advancement in addressing concerns about off-target infection and systemic toxicity that have hindered past approaches using live viruses in cancer therapy.

In vitro studies and mouse model experiments conducted by the Synthetic Biological Systems Lab have demonstrated the feasibility and efficacy of this dual-organism therapeutic platform. Microscopic imaging vividly illustrates the interplay, revealing Salmonella cells (stained magenta) infiltrating cancerous small cell lung carcinoma cells (grey), while the engineered picornavirus (depicted in cyan) radiates outward in a circular pattern as it propagates from the initial locus of infection. These results highlight the capacity for the system to permeate tumors and deliver a localized, amplified oncolytic effect with precise spatial control.

The interdisciplinary collaboration was led by Tal Danino, associate professor of biomedical engineering at Columbia Engineering, with vital contributions from virologist Charles M. Rice of The Rockefeller University. Their convergence of expertise in bacterial engineering and synthetic virology enabled the meticulous design of the CAPPSID system to balance therapeutic potency with safeguards that mitigate risks associated with live microbial therapies. The partnership exemplifies a new paradigm in cancer treatment research, focusing on engineering multi-organism therapies rather than single-agent interventions.

Beyond its therapeutic potential, the CAPPSID platform represents an adaptable scaffold for future development. The research team is actively pursuing extensions of this technology across a diverse array of tumor types, utilizing different viral vectors and bacterial strains to optimize efficacy and safety profiles. Their vision includes assembling a modular toolkit of engineered viruses capable of sensing intracellular environments and responding with bespoke therapeutic payloads. Moreover, by integrating bacterial strains already proven safe in clinical trials, the team aims to facilitate translational pathways that bring this promising therapy closer to human application.

A notable advantage of this system is its potential to overcome the challenges posed by tumor heterogeneity and physical barriers within solid malignancies. The combination of bacterial tropism and viral replication capacity enables deep penetration and widespread viral dissemination throughout tumors, a feat difficult to achieve with either bacteria or viruses alone. This dual delivery methodology could markedly improve therapeutic indices and reduce the chance of therapeutic resistance by promoting a multifaceted oncolytic effect.

Ensuring patient safety in therapies involving live microorganisms is paramount. CAPPSID’s unique safeguard—the requirement for a bacterial protease to activate viral maturation—adds a critical layer of biological containment. By tying viral life cycle progression to bacterial presence, the therapy effectively quarantines viral proliferation within the tumor microenvironment. This engineered dependency may serve as a blueprint for future microbiome-based therapies where tight spatial and functional control is essential.

The promising preclinical results position CAPPSID at the forefront of synthetic biology applications in oncology. As the research progresses from bench to bedside, rigorous clinical trials will be necessary to evaluate safety, dosing strategies, and therapeutic efficacy in human patients. The team’s commitment to clinical translation emphasizes the potential of living medicines that harness engineered microbial consortia to revolutionize cancer treatment paradigms.

In conjunction with advancing therapeutic design, the research group has filed a patent application to protect intellectual property surrounding their novel bacteria-virus system. Their work signals a transformative step toward realizing living therapies that orchestrate complex, cooperative interactions between multiple microorganisms to achieve precision targeting and controlled therapeutic action within cancerous tissues. This innovation may well herald a new era in bioengineered cancer therapeutics where the convergence of microbiology, synthetic biology, and oncology delivers unprecedented clinical outcomes.

With growing interest in oncolytic viruses and bacterial therapies independently, CAPPSID offers a trailblazing strategy that maximizes the intrinsic strengths of both modalities. As research evolves, it holds promise not only for improved treatment of solid tumors but also for the broader design of multi-microbial systems capable of tackling complex diseases. This synergy between engineered prokaryotes and viruses represents a bold leap forward in biomedical engineering, potentially overcoming key limitations that have constrained previous monotherapies.

Subject of Research: Engineered bacteria and viruses cooperating for targeted cancer therapy
Article Title: Engineered bacteria launch and control an oncolytic virus
News Publication Date: 15-Aug-2025
Web References:

• https://www.nature.com/articles/s41551-025-01476-8
• http://daninolab.nyc
• https://www.engineering.columbia.edu/faculty-staff/directory/tal-danino
• https://www.bme.columbia.edu/
• https://www.cancer.columbia.edu
• https://www.cuimc.columbia.edu
• https://datascience.columbia.edu
  Image Credits: Danino Lab
  Keywords: Biomedical engineering, oncolytic virus therapy, synthetic biology, bacterial cancer therapy, tumor targeting, Salmonella typhimurium, viral delivery systems, cancer treatment innovation